A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Launched by PFIZER · Jul 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called Palbociclib, which is used to treat a specific type of advanced breast cancer known as hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. The goal of the study is to understand how Palbociclib is used in everyday medical practice and how it affects patients compared to standard hormonal therapies. Researchers want to learn how long patients take Palbociclib and whether using it changes the need for chemotherapy later on.

To be eligible for this study, participants must be at least 18 years old and have been diagnosed with HR+/HER2- metastatic breast cancer. They should also be starting their first treatment with Palbociclib or other similar medications within a specific time period. Importantly, the study will use information collected from medical records without revealing any personal details about the patients. While this trial is currently active, it is not recruiting new participants at the moment.

Gender

ALL

Eligibility criteria

• • Patients are eligible for the study if they were 18 years of age or older at MBC diagnosis, had HR+/HER2- confirmed and initiated first line therapy (CDK4/6i, ET, CT, or other) in the metastatic setting during the period from February 2015 through June 2022 or data cutoff.